Thyroxine

Verify with FDA CVM →

298 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
298
Total Reports
39
Deaths Reported
1310.0%
Death Rate

Active Ingredients

Thyroxine

Administration Routes

OralUnknown

Species Affected

Dog 295
Cat 2
Human 1

Most Affected Breeds

Retriever - Labrador 45
Retriever - Golden 31
Crossbred Canine/dog 15
Beagle 14
Boxer (German Boxer) 9
Shepherd Dog - German 9
Shih Tzu 8
Collie - Border 8
Siberian Husky 8
Chihuahua 7

Most Reported Reactions

Vomiting 54
Lethargy (see also Central nervous system depression in 'Neurological') 49
Other abnormal test result NOS 39
Diarrhoea 33
Anorexia 28
Elevated alanine aminotransferase (ALT) 27
Death by euthanasia 23
Polydipsia 23
Elevated serum alkaline phosphatase (SAP) 22
Weight loss 20
Seizure NOS 20
Polyuria 20

Outcome Breakdown

Ongoing
122 (40.9%)
Outcome Unknown
71 (23.8%)
Recovered/Normal
65 (21.8%)
Euthanized
23 (7.7%)
Died
16 (5.4%)
Recovered with Sequela
1 (0.3%)

Data Summary

Metric Value
Total adverse event reports 298
Reports involving death 39
Case-fatality rate (reported events) 1310.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Thyroxine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 298 adverse event reports referencing Thyroxine, including 39 reports in which the animal died — a 1310.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Thyroxine. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Thyroxine reports are Dog (295 reports), Cat (2 reports), Human (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (45), Retriever - Golden (31), Crossbred Canine/dog (15) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Thyroxine are Vomiting (54), Lethargy (see also Central nervous system depression in 'Neurological') (49), Other abnormal test result NOS (39), Diarrhoea (33). Of the 298 reports with a coded outcome, Ongoing is the leading category at 40.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Thyroxine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial